T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “T-Cell Acute Lymphoblastic Leukemia – Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
T-Cell Acute Lymphoblastic Leukemia: Overview
T-cell acute lymphoblastic leukaemia (T-ALL) is a type of acute leukaemia meaning that it is aggressive and progresses quickly. It affects the lymphoid-cell-producing stem cells, in paticular a type of white blood cell called T lymphocytes as opposed to acute lymphoblastic leukaemia (ALL) which commonly affects B lymphocytes. T-cell acute lymphoblastic leukemia (T-ALL) represents approximately 12% to 15% of all newly diagnosed ALL cases in pediatric patients and is noteworthy for its unique clinical and biological features. There are no specific signs or symptoms which would allow a diagnosis of T-ALL to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. Most T-ALL disease recurrences occur within 2 years of diagnosis, and relapsed disease remains very difficult to salvage, with survival rates lower than 25%. Patients with newly diagnosed T-ALL are typically treated with risk-based multiagent chemotherapy regimens for 2 to 3 years, with or without cranial radiation therapy (CRT).
'T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-Cell Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and T-Cell Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth T-Cell Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the T-Cell Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-Cell Acute Lymphoblastic Leukemia Emerging Drugs
Further product details are provided in the report……..
T-Cell Acute Lymphoblastic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different T-Cell Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
T-Cell Acute Lymphoblastic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-Cell Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-Cell Acute Lymphoblastic Leukemia drugs.
T-Cell Acute Lymphoblastic Leukemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “T-Cell Acute Lymphoblastic Leukemia – Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
T-Cell Acute Lymphoblastic Leukemia: Overview
T-cell acute lymphoblastic leukaemia (T-ALL) is a type of acute leukaemia meaning that it is aggressive and progresses quickly. It affects the lymphoid-cell-producing stem cells, in paticular a type of white blood cell called T lymphocytes as opposed to acute lymphoblastic leukaemia (ALL) which commonly affects B lymphocytes. T-cell acute lymphoblastic leukemia (T-ALL) represents approximately 12% to 15% of all newly diagnosed ALL cases in pediatric patients and is noteworthy for its unique clinical and biological features. There are no specific signs or symptoms which would allow a diagnosis of T-ALL to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. Most T-ALL disease recurrences occur within 2 years of diagnosis, and relapsed disease remains very difficult to salvage, with survival rates lower than 25%. Patients with newly diagnosed T-ALL are typically treated with risk-based multiagent chemotherapy regimens for 2 to 3 years, with or without cranial radiation therapy (CRT).
'T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-Cell Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and T-Cell Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth T-Cell Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve T-Cell Acute Lymphoblastic Leukemia.
This segment of the T-Cell Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-Cell Acute Lymphoblastic Leukemia Emerging Drugs
- Isatuximab: Sanofi
- CPX-351: Jazz Pharmaceuticals
Further product details are provided in the report……..
T-Cell Acute Lymphoblastic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different T-Cell Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in T-Cell Acute Lymphoblastic Leukemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
T-Cell Acute Lymphoblastic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-Cell Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-Cell Acute Lymphoblastic Leukemia drugs.
T-Cell Acute Lymphoblastic Leukemia Report Insights
- T-Cell Acute Lymphoblastic Leukemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing T-Cell Acute Lymphoblastic Leukemia drugs?
- How many T-Cell Acute Lymphoblastic Leukemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-Cell Acute Lymphoblastic Leukemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T-Cell Acute Lymphoblastic Leukemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T-Cell Acute Lymphoblastic Leukemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
T-Cell Acute Lymphoblastic Leukemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Isatuximab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
CD7 CAR T cells: iCell Gene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
T-Cell Acute Lymphoblastic Leukemia Key Companies
T-Cell Acute Lymphoblastic Leukemia Key Products
T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
T-Cell Acute Lymphoblastic Leukemia Analyst Views
T-Cell Acute Lymphoblastic Leukemia Key Companies
Appendix
Executive Summary
T-Cell Acute Lymphoblastic Leukemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Isatuximab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
CD7 CAR T cells: iCell Gene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
T-Cell Acute Lymphoblastic Leukemia Key Companies
T-Cell Acute Lymphoblastic Leukemia Key Products
T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
T-Cell Acute Lymphoblastic Leukemia Analyst Views
T-Cell Acute Lymphoblastic Leukemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products